“…Hypopharyngeal squamous cell carcinoma (HSCC) occurs less frequently and accounts for 3–5% of all HNSCC (Hall et al , 2008; Cooper et al , 2009). In spite of considerable advances in multimodality therapy, including surgery, radiotherapy and chemotherapy, the overall survival rate for patients with HSCC is only 15–45% (Takes et al , 2012; Chan & Wei, 2013). Patients with HSCC are usually diagnosed at a late stage and local tumour recurrence and distant metastasis occur after conventional therapies (Takes et al , 2012; Chan and Wei, 2013).…”